Parkinson's disease

• A Phase IIa, Open Label Study to Evaluate the Safety of Afamelanotide in Patients with Early Parkinson's Disease Not authorised
  2022-502207-30-00 4 "Parkinson's Disease"
• An open-label, single-center study to evaluate the safety and test-retest characteristics of [11C]MODAG-005 as PET radioligand for imaging p … Pending
  2023-506965-72-00 1 "Parkinson Disease"
• A randomized, double-blind, placebo-controlled, single-ascending-dose study in healthy volunteers and a double-blind, placebo-controlled, mu … Pending
  2024-513411-27-00 1 "Parkinson’s disease"
• A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson’s Disease Pending
  2024-515448-22-00 4 "Parkinson"
• Assessment of the impairment of the serotoninergic system during the prodromal phase of Parkinson’s disease in SNCA mutation carriers by PET … Pending
  2024-516610-38-00 10
• A multi-part study to investigate MTX325 in healthy volunteers and patients with Parkinson's Disease Pending
  2024-517310-15-00 3 "Parkinson's Disease"
• EFFECTS OF SAFINAMIDE VERSUS PLACEBO ON PAIN IN PATIENTS WITH PARKINSON’S DISEASE WITH MOTOR FLUCTUATIONS: A RANDOMIZED, CONTROLLED, DOUBLE- … Pending
  2025-521512-20-00 5 "PARKINSON’S DISEASE WITH MOTOR FLUCTUATIONS"
• Evaluation of long-term safety in parkinsonian patients with intracerebroventricular administration of A-dopamine (anaerobic dopamine) - (DI … Recruiting
  2025-522261-30-00 7 2025-10-01 "Parkinson disease"
• Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients with Parkinson's Disease (ROCK-PD) Recruiting
  2024-517413-33-00 4 2026-02-03 "Idiopathic Parkinson's Disease"
• A Study in Adults with Parkinson's Disease and a Lack of Interest or Motivation to Test How Different Doses of IRL757 Given for Multiple Day … Recruiting
  2025-523612-37-00 3 2026-01-23 "Parkinson's Disease and Apathy"
• A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting
  2025-522683-32-00 5 2026-01-15 "Early-Stage Parkinson’s Disease (PD)"
• A Phase 3b open-label, randomised study of IPX203 in subjects with advanced Parkinson’s disease and motor fluctuations - ADIP study Recruiting
  2025-521772-57-00 5 2025-11-06 "Motor fluctuations in advanced Parkinson’s disease"
• INITIATE-LECIG: Intestinal levodopa + entacapone therapy (Lecigon®) to counteract dopaminergic desensitization and neuropsychiatric complica … Recruiting
  2025-521048-39-00 5 2025-10-28 "Parkinson Disease"
• Phase I, Open-Label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of BIA 28-6156 in Participants with Varying Degrees of R … Recruiting
  2025-520754-11-00 3 2025-08-25
• Management of Parkinson's disease if levodopa is broken down prematurely Recruiting
  2024-510629-24-00 4 2025-05-14
• Phase 1 study to evaluate [18F]ACI-15916 as a potential PET radioligand for imaging α-synuclein deposits in the brain of patients with suspe … Recruiting
  2024-515664-31-00 1 2025-03-04 "Parkinson's Disease"
• A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s dise … Recruiting
  2024-511110-21-00 1 2024-09-09 "Parkinson’s Disease"
• A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease (PASADENA) Recruiting
  2023-504472-24-00 4 2024-03-19 "Early Idiopathic Parkinson’s disease (PD)"
• Montelukast as disease modifying treatment in mild-moderate Parkinson’s disease (MONTPARK), a double-blind randomized placebo-controlled pha … Recruiting
  2023-504278-39-00 4 2024-02-27
• An adaptive, Phase 2, double-blind, randomized, placebo-controlled, multicenter study to evaluate the safety, tolerability, immunogenicity, … Recruiting
  2022-500292-31-00 4 2023-05-12 "Early stages of idiopathic Parkinson's Disease"
• Phase 2 Study of CVN424 Recruitment ended
  2024-516811-25-00 4 2025-05-15 "Parkinson Disease"
• A study of safety and tolerability (acceptability of potential side effects) of exidavnemab, at 2 different doses, in patients with Parkinso … Recruitment ended
  2024-511222-30-00 4 2024-10-22 "Multiple System Atrophy"
• A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson's Disease Recruitment ended
  2023-507132-21-00 10 2021-05-11 "Early Parkinson's disease"
• Please refer to the full title. Recruitment ended
  2024-516549-37-00 4 2021-04-12 "Treatment of Parkinson’s disease (PD)"

Showing 1–24 of 44 trials